U.S. Markets closed
  • Gold

    1,797.00
    -1.80 (-0.10%)
     
  • EUR/USD

    1.1600
    -0.0007 (-0.0580%)
     
  • 10-Yr Bond

    1.5290
    -0.0900 (-5.56%)
     
  • Vix

    16.98
    +1.00 (+6.26%)
     
  • GBP/USD

    1.3732
    -0.0010 (-0.0728%)
     
  • USD/JPY

    113.8280
    +0.0180 (+0.0158%)
     
  • BTC-USD

    58,874.08
    -1,834.72 (-3.02%)
     
  • CMC Crypto 200

    1,409.59
    -64.74 (-4.39%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • Nikkei 225

    28,857.68
    -240.56 (-0.83%)
     

Is Pfizer Stock a Buy After an FDA Panel Recommended Boosters for Ages 65 and Up?

·4 min read
Is Pfizer Stock a Buy After an FDA Panel Recommended Boosters for Ages 65 and Up?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

A partial victory is better than a complete loss. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are experiencing this firsthand. The two partners had hoped that a U.S. Food and Drug Administration (FDA) advisory committee would recommend COVID-19 vaccine boosters for all Americans ages 16 and up.